Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Sponsor: National Cancer Institute (NCI)
This observational or N/A phase trial investigates Recurrent Prostate Carcinoma and Stage I Prostate Cancer AJCC v7 and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 53 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)PRIMARY OBJECTIVES: I. To compare the two regimens on the proportion of patients with undetectable prostate-specific antigen (PSA) level (\< 0.2 ng/mL) at 44 weeks. SECONDARY OBJECTIVES: I. To assess the proportion of patients with PSA decline \>= 85% at 44 weeks on the combination therapy arm compared to that of bicalutamide monotherapy arm. II. To assess the distribution of best PSA response in each study arm. III. To assess the time to PSA progression in each arm of the study. IV. To assess the time to PSA nadir in each arm of the study. V. To assess the duration of PSA response in each arm of the study. VI. To characterize the PSA slope pre-study, during treatment, and off treatment. VII. To evaluate the safety and tolerability of MK-2206 (Akt inhibitor MK2206) in this patient population. VIII. To determine whether Gleason score has any effect on PSA response to treatment. IX. To determine whether prior hormonal therapy has any effect on PSA response to treatment. TERTIARY OBJECTIVES: I. Samples of the primary tumor specimen will be retrieved for banking and future analysis of the molecular profile of the primary prostate cancer (PC) tissues with emphasis on the androgen receptor...
PRIMARY OBJECTIVES:
I. To compare the two regimens on the proportion of patients with undetectable prostate-specific antigen (PSA) level (\< 0.2 ng/mL) at 44 weeks.
SECONDARY OBJECTIVES:
I. To assess the proportion of patients with PSA decline \>= 85% at 44 weeks on the combination therapy arm compared to that of bicalutamide monotherapy arm.
II. To assess the distribution of best PSA response in each study arm. III. To assess the time to PSA progression in each arm of the study. IV. To assess the time to PSA nadir in each arm of the study. V. To assess the duration of PSA response in each arm of the study. VI. To characterize the PSA slope pre-study, during treatment, and off treatment.
VII. To evaluate the safety and tolerability of MK-2206 (Akt inhibitor MK2206) in this patient population.
VIII. To determine whether Gleason score has any effect on PSA response to treatment.
IX. To determine whether prior hormonal therapy has any effect on PSA response to treatment.
TERTIARY OBJECTIVES:
I. Samples of the primary tumor specimen will be retrieved for banking and future analysis of the molecular profile of the primary prostate cancer (PC) tissues with emphasis on the androgen receptor (AR) and protein kinase B (Akt) upstream and downstream signaling pathways.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients undergo observation on weeks 1-12. Patients then receive bicalutamide\* orally (PO) once daily (QD) on weeks 13-44. Patients with a PSA decline of \>= 50% may continue on bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive Akt inhibitor MK2206\*\* PO once per week on weeks 1-44 and bicalutamide\* PO QD on weeks 13-44. Patients with a PSA decline of \>= 50% may continue on MK2206 and bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
NOTE: \*Patients may begin bicalutamide on weeks 4-11 if the disease worsens.
NOTE: \*\*Patients on Akt inhibitor MK2206 with a PSA \< 0.2 ng/mL by week 12 do not receive bicalutamide until PSA rises to \>= 0.2 ng/mL.
After completion of study therapy, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then every year for up to 10 years.
Status Flow
Change History
53 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE2 → None
-
Mar 2026 — May 2026 [monthly]
Active Not Recruiting PHASE2
-
Jan 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 48 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Nov 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate cancer.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .